Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 149


Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.

Wang X, Zhang W, Tripodi J, Lu M, Xu M, Najfeld V, Li Y, Hoffman R.

Blood. 2010 Dec 23;116(26):5972-82. doi: 10.1182/blood-2010-02-269696. Epub 2010 Sep 21.


Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Wang X, Zhang W, Ishii T, Sozer S, Wang J, Xu M, Hoffman R.

Cancer Res. 2009 Oct 1;69(19):7612-8. doi: 10.1158/0008-5472.CAN-09-1823. Epub 2009 Sep 14.


Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.

Shi J, Zhao Y, Ishii T, Hu W, Sozer S, Zhang W, Bruno E, Lindgren V, Xu M, Hoffman R.

Cancer Res. 2007 Jul 1;67(13):6417-24.


Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents.

Araki H, Mahmud N, Milhem M, Nunez R, Xu M, Beam CA, Hoffman R.

Exp Hematol. 2006 Feb;34(2):140-9.


Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential.

Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N.

Blood. 2007 Apr 15;109(8):3570-8. Epub 2006 Dec 21.


Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.

Ishii T, Zhao Y, Sozer S, Shi J, Zhang W, Hoffman R, Xu M.

Exp Hematol. 2007 Nov;35(11):1633-40. Epub 2007 Aug 30.


The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.

James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, Lippert E, Mahon FX, Pasquet JM, Etienne G, Delhommeau F, Giraudier S, Vainchenker W, de Verneuil H.

Blood. 2008 Sep 15;112(6):2429-38. doi: 10.1182/blood-2008-02-137877. Epub 2008 Jul 8.


The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

Lu M, Xia L, Li Y, Wang X, Hoffman R.

Blood. 2014 Jul 31;124(5):771-9. doi: 10.1182/blood-2013-11-536854. Epub 2014 May 28.


Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.

Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, Hoffman R.

Blood. 2004 Jun 1;103(11):4102-10. Epub 2004 Feb 19.


Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues.

Araki H, Baluchamy S, Yoshinaga K, Petro B, Petiwala S, Parajuli R, Milhem M, Lavelle D, DeSimone J, Mahmud N.

Exp Hematol. 2009 Sep;37(9):1084-95. doi: 10.1016/j.exphem.2009.05.012. Epub 2009 Jun 6.


Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells.

Mahmud N, Petro B, Baluchamy S, Li X, Taioli S, Lavelle D, Quigley JG, Suphangul M, Araki H.

Biol Blood Marrow Transplant. 2014 Apr;20(4):480-9. doi: 10.1016/j.bbmt.2013.12.562. Epub 2013 Dec 26.


The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis.

Xu M, Bruno E, Chao J, Ni H, Lindgren V, Nunez R, Mahmud N, Finazzi G, Fruchtman SM, Popat U, Liu E, Prchal JT, Rondelli D, Barosi G, Hoffman R.

Blood. 2005 Feb 15;105(4):1699-705. Epub 2004 Oct 7.


Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms.

Fung TK, Cheung AM, Kwong YL, Liang R, Leung AY.

Leuk Res. 2010 Oct;34(10):1390-4. doi: 10.1016/j.leukres.2010.01.028. Epub 2010 Feb 18.


C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients.

Wang X, Cho SY, Hu CS, Chen D, Roboz J, Hoffman R.

Exp Hematol. 2015 Feb;43(2):100-9.e1. doi: 10.1016/j.exphem.2014.10.013. Epub 2014 Nov 8.


Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo.

Sozer S, Ishii T, Fiel MI, Wang J, Wang X, Zhang W, Godbold J, Xu M, Hoffman R.

Blood Cells Mol Dis. 2009 Nov-Dec;43(3):304-12. doi: 10.1016/j.bcmd.2009.08.005. Epub 2009 Sep 16.


Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice.

Kollet O, Spiegel A, Peled A, Petit I, Byk T, Hershkoviz R, Guetta E, Barkai G, Nagler A, Lapidot T.

Blood. 2001 May 15;97(10):3283-91.


Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis.

Chaligné R, James C, Tonetti C, Besancenot R, Le Couédic JP, Fava F, Mazurier F, Godin I, Maloum K, Larbret F, Lécluse Y, Vainchenker W, Giraudier S.

Blood. 2007 Nov 15;110(10):3735-43. Epub 2007 Aug 20.


Rational therapeutic options for patients with myeloproliferative neoplasms.

Hoffman R.

Trans Am Clin Climatol Assoc. 2011;122:11-26. Review.


SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection.

Wang J, Kimura T, Asada R, Harada S, Yokota S, Kawamoto Y, Fujimura Y, Tsuji T, Ikehara S, Sonoda Y.

Blood. 2003 Apr 15;101(8):2924-31. Epub 2002 Dec 12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk